@article{37f2e80ee7db47c5a4c2a98a931b5835,
title = "Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial",
abstract = "Currently, there is limited data regarding the effectiveness of standard subsequent line therapies such as endocrine therapy, chemotherapy, or targeted agents after progression on CDK4/6 inhibitor-based regimens. This paper describes time-to-treatment failure beyond progression on palbociclib or palbociclib+endocrine therapy in patients enrolled in the phase II, multicenter TREnd trial. Our results indicate that there is limited benefit from post-palbociclib treatment, regardless of the type of therapy received. A small population of long responders were identified who demonstrated ongoing benefit from a subsequent line of endocrine therapy after progression to palbociclib-based regimens. A translational research program is ongoing on this population of outliers.",
keywords = "Best sequence, CDK4/6 inhibitors, Metastatic breast cancer, Palbociclib, TREnd trial",
author = "Lorenzo Rossi and Chiara Biagioni and Amelia McCartney and Ilenia Migliaccio and Giuseppe Curigliano and Giuseppina Sanna and Erica Moretti and Minisini, \{Alessandro M.\} and Saverio Cinieri and Carlo Tondini and Grazia Arpino and Antonio Bernardo and Angelo Martignetti and Emanuela Risi and Marta Pestrin and Luca Boni and Matteo Benelli and Laura Biganzoli and \{Di Leo\}, Angelo and Luca Malorni",
note = "Funding Information: GC has received research funding from Pfizer, Roche, Novartis, Sanofi, Celgene, Servier, Orion, AstraZeneca, Seattle Genetics, AbbVie, Tesaro, BMS, Merck-Serono, Medivation, Medimmune and Bayer, and has had consulting/ advisory role from Roche, Seattle Genetics, Novartis, Lilly, Pfizer, Foundation Medicine, Nanostring, Samsung and Mylan. SC has had consulting role for Lilly. GA has received research funding from Novartis, and has had a consulting/advisory role with Pfizer, Novartis and Lilly. LBi has received research funding from Celgene, Genomic Health and Novartis, and has had a consulting/advisory role with AstraZeneca, Celgene, Eisai, Genomic Health, Ipsen, Lilly, Novartis, Pfizer, Pierre Fabre and Roche. ADL has received research funding from AstraZeneca, Pfizer and Pierre-Fabre, and has had a consulting/advisory role with AstraZeneca, Bayer, Celgene, Daichi-Sankyo, Eisai, Genomic Health, Ipsen, Lilly, Novartis, Pierre-Fabre, Pfizer and Roche. LM has received research funding from Pfizer and has had consulting/advisory role for Pfizer and Novartis. All other authors have nothing to disclose. Funding Information: We thank the patients and their families who participated in TREnd. The study was funded by an investigator-initiated research grant from Pfizer and sponsored by Fondazione Sandro Pitigliani per la lotta contro i tumori ONLUS, Prato (Italy). We acknowledge the generous support provided by the Breast Cancer Research Foundation (BCRF) (New York, USA) for the grant BCRF-18-037 (to ADL) and Associazione Italiana per la Ricerca sul Cancro (AIRC) for grant MFAG 18880 (to LM). Publisher Copyright: {\textcopyright} 2019 The Author(s).",
year = "2019",
month = may,
day = "29",
doi = "10.1186/s13058-019-1149-5",
language = "English",
volume = "21",
journal = "Breast Cancer Research",
issn = "1465-542X",
publisher = "BioMed Central",
number = "1",
}
SDG 3 Good Health and Well-being